{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:07:56Z","timestamp":1780657676102,"version":"3.54.1"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Previous studies suggested that patients with chronic lymphocytic leukaemia (CLL) are at a three\u2010 to fivefold increased risk of developing a second lymphoproliferative disorder (LPD). This observational cohort study used the Mayo Clinic CLL Database to identify factors associated with developing a second LPD. A second LPD was identified in 26 (2\u00b77%) of 962 CLL patients during a median follow\u2010up of 3\u00b73\u2003years. Diffuse large B\u2010cell lymphoma was the most common subtype of secondary LPD (12 of 26 cases). Patients previously treated for CLL had a trend toward higher prevalence of second LPD (4%) compared with previously untreated patients (2%; <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7053). More strikingly, patients treated with purine nucleoside analogues (PNA) had a significantly increased risk of subsequent second LPD (5\u00b72%) compared with patients who had not received PNA (1\u00b79%; <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7008). No statistically significant association was observed between risk of second LPD and other CLL characteristics (ZAP\u201070, CD38, IgV<jats:sub><jats:italic>H<\/jats:italic><\/jats:sub> mutation status or cytogenetic abnormalities). In this series, prior treatments with PNA or anthracyclines were the only significant factors associated with risk of developing a second LPD in patients with CLL. Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2007.06801.x","type":"journal-article","created":{"date-parts":[[2010,7,26]],"date-time":"2010-07-26T10:33:02Z","timestamp":1280140382000},"page":"398-404","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia"],"prefix":"10.1111","volume":"139","author":[{"given":"Kami","family":"Maddocks\u2010Christianson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive S.","family":"Zent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Reinalda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Call","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tait D.","family":"Shanafelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200205000-00009"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197802)41:2<422::AID-CNCR2820410207>3.0.CO;2-X"},{"key":"e_1_2_6_4_1","first-page":"27","article-title":"Impairments in immune cell function in B cell chronic lymphocytic leukemia","volume":"25","author":"Bartik M.M.","year":"1998","journal-title":"Seminars in Oncology"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"(Abstract)14","DOI":"10.1182\/blood.V104.11.14.14","article-title":"Clinical characteristics and outcome of a large series of patients with chronic lymphocytic leukemia (CLL) according to ZAP\u201070 expression","volume":"104","author":"Bosch F.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)62215-0"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2454"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.19.3325"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04265.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054836"},{"key":"e_1_2_6_11_1","first-page":"117","article-title":"Chronic lymphocytic leukemia in (Richter's) transformation","volume":"25","author":"Giles F.J.","year":"1998","journal-title":"Seminars in Oncology"},{"key":"e_1_2_6_12_1","first-page":"101","article-title":"The immune response to phichi174 in man. IV. Primary and secondary antibody production in patients with chronic lymphatic leukaemia","volume":"21","author":"Hamblin T.J.","year":"1975","journal-title":"Clinical and Experimental Immunology"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.53.4.248"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03149.x"},{"key":"e_1_2_6_15_1","first-page":"346","article-title":"Identification of a global gene expression signature of B\u2010chronic lymphocytic leukemia","volume":"1","author":"Jelinek D.F.","year":"2003","journal-title":"Molecular Cancer Research"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91681-5"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V95.3.1023.003k07_1023_1031","article-title":"Hodgkin and Reed\u2010Sternberg\u2010like cells in B\u2010cell chronic lymphocytic leukemia represent the outgrowth of single germinal\u2010center B\u2010cell\u2010derived clones: potential precursors of Hodgkin and Reed\u2010Sternberg cells in Hodgkin's disease","volume":"95","author":"Kanzler H.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1165"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03357.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01765.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2319"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.2.448"},{"key":"e_1_2_6_23_1","article-title":"Transformation to Richter's syndrome or prolymphocytic leukemia (PLL), and other second hematologic malignancies in patients with chronic lymphocytic leukemia (CLL)","volume":"94","author":"Morrison V.A.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1320-5463.2003.01455.x"},{"issue":"1","key":"e_1_2_6_26_1","first-page":"429a","article-title":"Fludarabine therapy may precipitate large cell transformation in chronic lymphocytic leukemia but not in follicular lymphoma","volume":"92","author":"Pocock C.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_2_6_28_1","first-page":"285","article-title":"Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia","volume":"4","author":"Richter M.","year":"1928","journal-title":"American Journal of Pathology"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245330400018599"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.09.031"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1985"},{"key":"e_1_2_6_32_1","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2000.18.19.3323","article-title":"Epstein\u2010Barr virus, the CNS, and AIDS\u2010related lymphomas: as close as flame to smoke","volume":"18","author":"Scadden D.T.","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22672"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2281"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-6-200609190-00007"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.9492"},{"key":"e_1_2_6_37_1","first-page":"1151","article-title":"Detection of Epstein\u2010Barr virus in transformations of low\u2010grade B\u2010cell lymphomas after fludarabine treatment","volume":"10","author":"Shields D.J.","year":"1997","journal-title":"Modern Pathology"},{"key":"e_1_2_6_38_1","first-page":"(Abstract)295","article-title":"Fludarabine (FAMP) and risk of occurrence of Ricthter's syndrome among B\u2010CLL","volume":"96","author":"Tabuteau S.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.09.008"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403249"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.18.1422"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20773"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.016"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-004-0013-7"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2007.06801.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2007.06801.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T04:17:41Z","timestamp":1695961061000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2007.06801.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1111\/j.1365-2141.2007.06801.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06801.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"2007-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}